Bharat Biotech’s Covaxin gets approval for next phase of trials on 2-18 year-olds | News – Times of India Videos

May 12, 2021, 03:07PM ISTSource: Times Now

Bharat Biotech’s COVID-19 vaccine Covaxin was recommended by an expert panel for phase II/III clinical trials on those aged between two to 18 years. Bharat Biotech has earlier sought permission to conduct phase II/III clinical trials to evaluate the safety, reactogenicity and immunogenicity of Covaxin jabs in children aged 2 to 18 years. The development is significant considering the fact that India might witness the third wave of covid-19 later in the year.


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.